1. O Grupo de Escrita para o Ensaio PEPI “Efeitos dos regimes de estrogénio ou estrogénio/progestina nos factores de risco de doenças cardíacas em mulheres na pós-menopausa: o Ensaio de Intervenções de Estrogénio/Progestina Pós-Menopausa (PEPI)”. JAMA 273 (1995): 199-208
2. Collins P, Beale CM, Rosano GMC “O estrogénio como bloqueador dos canais de cálcio”. Eur Heart J 17 ( Suppl (1996): 27-31
3. Grady D, Wenger NK, Herrington D, et al. “A terapia hormonal pós-menopausa aumenta o risco de doença tromboembólica venosa: o estudo de substituição do coração e do estrogénio”. Ann Intern Med 132 (2000): 689-96
4. Kamali P, Muller T, Lang U, Clapp JF “Cardiovascular responses of perimenopausal women to hormonal replacement therapy”. Am J Obstet Gynecol 182 (2000): 17-22
5. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH “Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women”. JAMA 287 (2002): 2668-76
6. Crane MG, Harris JJ “Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system”. Am J Med Sci 276 (1978): 33-55
7. Barrett-Connor E, Bush TL “Estrogen and coronary heart disease in women”. JAMA 265 (1991): 1861-7
8. Wren BG, Routledge DA “Blood pressure changes: oestrogens in climacteric women”. Med J Aust 2 (1981): 528-31
9. Schwartz J, Freeman R, Frishman W “Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women”. J Clin Pharmacol 35 (1995): 1-16
10. Herrington DM, Reboussin DM, Brosniham KB, et al. “Effects of estrogen replacement on the progression of coronaryary-artery atherosclerosis”. N Engl J Med 343 (2000): 522-9
11. Jick H, Dinan B, Rothman KJ “Estrogénios não-contraceptivos e enfarte do miocárdio não-fatal”. JAMA 239 (1978): 1407-8
12. Crane MG, Harris JJ, Winsor W 3d “Hypertension, oral contraceptive agents, and conjugated estrogens”. Ann Intern Med 74 (1971): 13-21
13. Cerner Multum, Inc., Cerner Multum. “UK Summary of Product Characteristics” (Resumo das Características do Produto no Reino Unido). O 0
14. Grady D, Rubin SM, Petiti DB, et al. “Hormonoterapia para prevenir doenças e prolongar a vida em mulheres na pós-menopausa”. Ann Intern Med 117 (1992): 1016-36
15. Miller J, Chan BK, Nelson HD “Postmenopausal estrogen replacement and risk for venous tromboembolism: a systematic review and meta-analysis for the U.S. preventive services task force”. Ann Intern Med 136 (2002): 680-90
16. Stampfer MJ, Colditz GA, Willett WC, et al. “Postmenopausal estrogen and cardiovascular disease. Seguimento de dez anos do Estudo de Saúde dos Enfermeiros”. N Engl J Med 325 (1991): 756-62
17. “Informação sobre o produto. Premarin (estrogénios conjugados)”. Wyeth-Ayerst Laboratories, Philadelphia, PA.
18. Cerner Multum, Inc. “Australian Product Information”. O 0
19. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, SchenckGustafsson K “A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease”. J Hypertens 17 (1999): 1379-86
20. Gordeuk VR, Brittenham GM, Hughes M, Keating LJ, Opplt JJ “High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial”. Am J Clin Nutr 46 (1987): 1029-34
21. Petitti DB “Terapia de substituição hormonal e prevenção de doenças cardíacas: a experimentação supera a observação”. JAMA 280 (1998): 650-2
22. “Informação sobre o produto”. Enjuvia (estrogénios conjugados)”. Barr Pharmaceuticals Inc, Pomona, NY.
23. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women”. JAMA 280 (1998): 605-13
24. Herrington DM “The HERS Trial results: paradigms lost?” (Os resultados do ensaio HERS: paradigmas perdidos?) Ann Intern Med 131 (1999): 463-6
25. Mendelsohn ME, Karas RH “The protective effects of estrogen on the cardiovascular system” (Os efeitos protectores do estrogénio no sistema cardiovascular). N Engl J Med 340 (1999): 1801-11
26. Sidney S, Petitti DB, Quesenberry CP “Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women”. Ann Intern Med 127 (1997): 501-8
27. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS “Estrogénio não-contraceptivo e enfarte do miocárdio em mulheres jovens”. JAMA 244 (1980): 339-42
28. Barrett-Connor E, Wingard DL, Criqui MH “Postmenopausal estrogen use and heart disease risk factors in the 1980s”. Rancho Bernardo, Califórnia, revisitado”. JAMA 261 (1989): 1095-2100
29. Belchetz PE “Tratamento hormonal de mulheres na pós-menopausa”. N Engl J Med 330 (1994): 1062-71
30. Boston Collaborative Drug Surveilance Program “Doença da vesícula biliar confirmada cirurgicamente, tromboembolismo venoso, e tumores mamários em relação à terapia de estrogénio pós-menopausa”. N Engl J Med 290 (1974): 15-9
31. McClennan BL “Colite isquémica secundária a Premarin: relato de um caso”. Dis Colon Rectum 19 (1976): 618-20
32. Perusse R, Morency R “Pigmentação oral induzida por Premarin”. Cutis 48 (1991): 61-4
33. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T “Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women”. Circulação 106 (2002): 1771-6
34. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR “Effects of low-dose continuous combined estrogens and medroxyprogesterone acettate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women”. Am J Obstet Gynecol 185 (2001): 1180-5
35. OrrWalker BJ, Horne AM, Evans MC, Grey AB, Murray MAF, McNeil AR, Reid IR “A terapia de substituição hormonal causa uma alcalose respiratória em mulheres normais na pós-menopausa”. J Clin Endocrinol Metab 84 (1999): 1997-2001
36. Civitelli R, Pilgram TK, Dotson M, et al. “Alveolar and Postcranial Bone Density in Postmenopausal Women Receiving Hormone/Estrogen Replacement Therapy”: Um Ensaio Randomizado, Duplo-cego, Placebo-Controlado”. Arch Intern Med 162 (2002): 1409-15
37. Steiger MJ, Quinn NP “Terapia de substituição hormonal induzida por coréia”. BMJ 302 (1991): 762
38. Jick SS, Walker AM, Jick H “Estrogénios conjugados e doença fibrocística da mama”. Am J Epidemiol 124 (1986): 746-51
39. Pastides H, Najjar MA, Kelsey JL “Estrogen replacement therapy and fibrocystic breast disease”. Am J Prev Med 3 (1987): 282-6
40. Oppenheim G “A case of rapid mood cycling with estrogen: implications for therapy”. J Clin Psychiatry 45 (1984): 34-5
41. Aldinger K, Ben-Menachem Y, Whalen G “Focal nodular hyperplasia do fígado associada a estrogénios de alta dose”. Arch Intern Med 137 (1977): 357-9
42. Conter RL, Longmire WP Jr. “Hemangiomas hepáticos recorrentes. Possível associação com terapia de estrogénio”. Ann Surg 207 (1988): 115-9
43. Searcy CJ, Kushner M, Nell P, Beckmann CR “Anaphylactic reaction to intravenous conjugated estrogenes”. Clin Pharm 6 (1987): 74-6
44. Caucino JA, Armenaka M, Rosenstreich DL “Anaphylaxis associado a uma mudança na formulação de corantes pré-marínicos”. Ann Alergia 72 (1994): 33-5
45. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW “Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases”. Am J Epidemiol 114 (1981): 497-506
46. Thomas DB, Persing JP, Hutchinson WB “Estrogénios exógenos e outros factores de risco de cancro da mama em mulheres com doenças benignas da mama”. J Natl Cancer Inst 69 (1982): 1017-25
47. Buring JE, Bain CJ, Ehrmann RL “Conjugated estrogen use and risk of endometrial cancer” (Utilização de estrogénios conjugados e risco de cancro endometrial). Am J Epidemiol 124 (1986): 434-41
48. Gordon J, Reagan JW, Finkle WD, Ziel HK “Estrogénio e carcinoma endometrial”. An independent pathology review supporting original risk estimate”. N Engl J Med 297 (1977): 570-1
49. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA “Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-age women”. JAMA 274 (1995): 137-42
50. Ziel HK, Finkle WD “Aumento do risco de carcinoma endometrial entre os utilizadores de estrogénios conjugados”. N Engl J Med 293 (1975): 1167-70
51. Woodruff JD, Pickar JH “Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone”. Am J Obstet Gynecol 170 (1994): 1213-23
52. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S “Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study”. Am J Epidemiol 134 (1991): 1386-95
53. Obrink A, Bunne G, Collen J, Tjernberg B “Endometrial cancer and exogenous estrogenous estrogens”. Acta Obstet Gynecol Scand 58 (1979): 123
54. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S “Estrogen replacement therapy and the risk of breast cancer: results from the casecontrol surveillance study”. Am J Epidemiol 134 (1991): 1375-85
55. Gray LA Sr, Christopherson WM, Hoover RN “Estrogénicos e carcinoma endometrial”. Obstet Gynecol 49 (1977): 385-9
56. Colditz GA, Hankinson SE, Hunter DJ, et al. “The use of estrogens and progestins and the risk of breast cancer in postmenopausal women”. N Engl J Med 332 (1995): 1589-93
57. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K “Estrogénios conjugados e risco de cancro da mama nas mulheres”. J Natl Cancer Inst 67 (1981): 815-20
58. The Writing Group for the PEPI Trial “Effects of hormone replacement therapy on endometrial histology in postmenopausal women”. JAMA 275 (1996): 370-5
59. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D “Risco de cancro endometrial localizado e generalizado em relação ao uso recente e descontinuado de estrogénios conjugados”. N Engl J Med 313 (1985): 969-72
60. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C “Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogenes: results of a prospective study”. BMJ 298 (1989): 147-51
61. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C “The risk of breast cancer after estrogen and estrogen-progestin replacement”. N Engl J Med 321 (1989): 293-7
62. Gapstur SM, Morrow M, Sellers TA “Hormone replacement therapy and risk of breast cancer with a favourable histology: results of the Iowa women’s health study”. JAMA 281 (1999): 2091-7
63. Greendale GA, Reboussin BA, Sie A, et al. “Effects of estrogen and estrogen-progestin on mammographic parenchymal density”. Ann Intern Med 130 (1999): 262-9
64. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R “Endometrial cancer and estrogen use. Relatório de um grande estudo de caso-controlo”. N Engl J Med 300 (1979): 9-13